288. Autoimmune acquired coagulation factor deficiency Clinical trials / Disease details

Clinical trials : 206 / Drugs : 231 - (DrugBank : 28) / Drug target genes : 10 - Drug target pathways : 21

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02932618 (ClinicalTrials.gov)	December 18, 2017	12/10/2016	A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)	A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease	Von Willebrand Disease	Biological: von Willebrand factor (Recombinant);Biological: Antihemophilic Factor (Recombinant)	Baxalta now part of Shire	Takeda Development Center Americas, Inc.	Recruiting	N/A	17 Years	All	34	Phase 3	United States;Austria;Belgium;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom
2	NCT02973087 (ClinicalTrials.gov)	November 16, 2017	22/11/2016	rVWF IN PROPHYLAXIS	A PROSPECTIVE, PHASE 3, OPEN-LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE	Von Willebrand Disease	Biological: von Willebrand factor (Recombinant);Biological: Antihemophilic Factor (Recombinant)	Takeda	Baxalta Innovations GmbH, now part of Shire	Completed	18 Years	N/A	All	29	Phase 3	United States;Canada;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey